The phase III KEYNOTE-522 trial investigating Keytruda in combination with chemotherapy as neoadjuvant treatment and then continuing as an adjuvant treatment after surgery met its dual primary endpoint of event-free survival for the treatment of patients with high-risk early-stage triple-negative breast cancer.
“Patient stories, as you know, can either make or break a story,” said Laurie McGinley, a former health and science editor at The Washington Post who is now on the board of Patient Action for Cancer Research, or PACR, a new advocacy organization aimed at organizing and amplifying patient voices in an effort to protect life-saving federal health research.
